Cytokinetics, Incorporated (CYTK) EVP Fady Ibraham Malik Sells 7,321 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 7,321 shares of the firm’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $13.39, for a total transaction of $98,028.19. Following the sale, the executive vice president now owns 47,540 shares in the company, valued at $636,560.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) traded up $0.70 during midday trading on Friday, reaching $13.60. 670,702 shares of the company’s stock were exchanged, compared to its average volume of 433,057. The company has a quick ratio of 10.21, a current ratio of 7.60 and a debt-to-equity ratio of 0.14.

Cytokinetics, (NASDAQ:CYTK) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.04. The company had revenue of $6.18 million for the quarter, compared to the consensus estimate of $5.35 million. Cytokinetics, had a negative net margin of 172.27% and a negative return on equity of 62.64%. equities research analysts predict that Cytokinetics, Incorporated will post -2.39 earnings per share for the current year.

WARNING: “Cytokinetics, Incorporated (CYTK) EVP Fady Ibraham Malik Sells 7,321 Shares” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/03/cytokinetics-incorporated-cytk-evp-fady-ibraham-malik-sells-7321-shares.html.

Institutional investors have recently bought and sold shares of the company. Prudential Financial Inc. bought a new stake in shares of Cytokinetics, in the 2nd quarter worth about $913,000. Janus Henderson Group PLC bought a new stake in shares of Cytokinetics, in the 2nd quarter worth about $32,488,000. Fox Run Management L.L.C. bought a new stake in shares of Cytokinetics, in the 2nd quarter worth about $436,000. Swiss National Bank bought a new stake in shares of Cytokinetics, in the 2nd quarter worth about $697,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of Cytokinetics, by 56.2% in the 2nd quarter. Russell Investments Group Ltd. now owns 259,833 shares of the biopharmaceutical company’s stock worth $3,144,000 after buying an additional 93,504 shares during the last quarter. Hedge funds and other institutional investors own 70.94% of the company’s stock.

Several analysts have recently commented on the stock. TheStreet downgraded shares of Cytokinetics, from a “c” rating to a “d” rating in a research report on Friday, October 27th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Cytokinetics, in a research report on Sunday, October 29th. Cowen and Company restated a “buy” rating and set a $19.00 price objective on shares of Cytokinetics, in a research report on Friday, August 4th. HC Wainwright set a $26.00 price objective on shares of Cytokinetics, and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Zacks Investment Research upgraded shares of Cytokinetics, from a “hold” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Monday, August 7th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $21.60.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Insider Buying and Selling by Quarter for Cytokinetics, (NASDAQ:CYTK)

What are top analysts saying about Cytokinetics Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Cytokinetics Incorporated and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit